Abu Dhabi-based G42 Healthcare has extended the world’s first Phase III trials of an inactivated COVID-19 vaccine to a new centre in Bahrain with the first volunteers being vaccinated in the Kingdom.
The new phase of the #4Humanity trials will reinforce the ongoing collaboration between public health bodies in the UAE and Bahrain in combating the impact of the COVID-19 pandemic and increase the number of individuals who will participate in the trials.
In total, up to 6,000 volunteers are being sought for the new centre that will be the third in the ongoing trials after those in the UAE at the Abu Dhabi National Exhibition Centre in Abu Dhabi and Al Qarain Health Center in Sharjah.
This is an extension of the ongoing 4Humanity program by G42 Healthcare, the phase III clinical trials of the inactivated vaccine developed by Sinopharm CNBG in China that commenced in the UAE on 16 July. this is an extension of current programme in the UAE with the same vaccines used from Sinopharm, the world’s sixth largest vaccine producer, will be used in Bahrain.
G42 Healthcare CEO Ashish Koshy added: “It was always part of our original plan to open several centres to ensure the broadest impact and opportunity for individuals to participate and join the 4Humanity campaign. There has been a hugely enthusiastic response from the Ministry of Health and other public health bodies in Bahrain to work with us on the trials and to encourage their communities to volunteer in the trials.
“The expansion will also help to boost the overall numbers of people participating in the test to enable similar numbers to other international trials underway in nations with much larger populations. We are also anticipating an expansion of the our centre network in the UAE to be announced shortly.”
The trials began in Abu Dhabi on 16th July and are being managed by G4 Healthcare in partnership with the Department of Health - Abu Dhabi, the UAE Ministry of Health and Prevention (MOHAP) and Abu Dhabi Health Services Company (SEHA). They are being conducted following the international guidelines stipulated by the World Health Organization (WHO) and the United States Food & Drug Administration (USFDA).
The Phase III clinical trials follow the success of the Phase I and Phase II trials conducted by Sinopharm in China, which resulted in 100% of the volunteers generating antibodies to SARS-CoV-2, the virus that causes COVID-19, after two doses in 28 days. The new centre for the Phase III trials is open to individual volunteers aged between 18 and 60 living in Bahrain and will last for six to twelve months, with the volunteers required to be available for follow ups during this time.
DOHA, Qatar: Since periodontitis and COVID-19 are both associated with systemic inflammation, researchers from Qatar University and Hamad Medical ...
Infection control and prevention measures commonly observed in the dental practice are safe and effective, but hygiene routines need to be known, understood...
LEIPZIG, Germany: Given that little time has passed since the outbreak of SARS-CoV-2, it comes as no surprise that only sparse data on COVID-19 is available...
JEDDAH, Saudi Arabia: A recent study conducted by dental researchers from Saudi Arabia’s Batterjee Medical College sought to better understand how ...
BRUSSELS, Belgium: More than a year into the COVID-19 pandemic, its seismic impact on different elements of the dental profession is becoming clearer. In ...
CAPP (Centre for Advanced Professional Practices) organises its events online and in a digitised format. This allows dental professionals around the world ...
LEIPZIG, Germany: Even though millions of people suffer from anxiety and depression, according to the World Health Organization, psychiatric disorders often...
The COVID-19 recovery rate in GCC countries is significantly higher than the global average, according to new research. An average of 81.4 per cent of cases...
As precautionary measures are adapted across different professions in the wake of the COVID-19 outbreak, dentists are being extra cautious to protect ...
KRIENS, Switzerland: During the ongoing COVID-19 crisis, the dental profession forms one of the most threatened groups. Close contact with patients, ...
Live webinar
Fri. 19 July 2024
4:00 am UAE (Dubai)
Live webinar
Wed. 7 August 2024
2:00 am UAE (Dubai)
Live webinar
Wed. 14 August 2024
3:00 am UAE (Dubai)
Live webinar
Wed. 14 August 2024
8:30 pm UAE (Dubai)
Live webinar
Wed. 21 August 2024
5:00 pm UAE (Dubai)
Dr. Jim Lai DMD, MSc(Perio), EdD, FRCD(C)
Live webinar
Thu. 29 August 2024
4:00 am UAE (Dubai)
Live webinar
Mon. 2 September 2024
1:00 pm UAE (Dubai)
To post a reply please login or register